Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study

BACKGROUND: GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and leukotriene B4 and 5-oxo-6,8,11,14-eicosatetraenoic acid. We have previously reported that GSK2190915 100 mg daily inhibits early and late asthmatic responses to inhaled aller...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Boyce, Malcolm, Norris, Virginia, Kent, Sandra E, Bentley, Jane H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862733/
https://www.ncbi.nlm.nih.gov/pubmed/24357936
http://dx.doi.org/10.2147/IJGM.S51364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862733/
https://www.ncbi.nlm.nih.gov/pubmed/24357936
http://dx.doi.org/10.2147/IJGM.S51364

Ejemplares similares